This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Hepatic cirrhosis is a serious condition in which the liver becomes severely scarred, disrupting its normal functioning. This scarring is caused by a variety of conditions, such as long-term alcohol abuse, viral hepatitis, or other causes of chronic inflammation. As the liver becomes more and more damaged, it cannot perform its essential functions, such as filtering toxins from the blood, producing bile, and breaking down fat and proteins. The main symptoms of hepatic cirrhosis include fatigue, jaundice (yellowing of the skin and eyes), fluid buildup in the legs and abdomen, loss of appetite, nausea, vomiting, and weight loss. Other complications of the condition include confusion, bleeding disorders, and increased risk of infection. In advanced cases, hepatic cirrhosis can lead to liver failure, which can be fatal. Treatment for hepatic cirrhosis depends on the underlying cause of the condition. For example, if alcohol is the cause, the patient must abstain from drinking alcohol. Other treatments may include medications to reduce inflammation, reduce fluid buildup, and improve liver function. Liver transplantation may be necessary in some cases. Hepatic cirrhosis is a serious condition that can have life-threatening consequences if untreated. It is important to be aware of the risk factors and to seek medical attention if any symptoms develop. Early diagnosis and treatment are essential in order to reduce the risk of complications and improve the patient’s prognosis.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States